Celgene (NASDAQ: CELG) fell Thursday after the company pulled an application for its multiple myeloma drug from European Union regulators after a request for more mature data. The stock was also likely hurt by unanimous approval from a...(Click the story link or go to http://www.marketintelligencecenter.com for the full story)